Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP3 | P15309 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.40 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6273785 | 1.00 | ACP3 (0.47) | ACP3TSHRMEN1KMT2ALMNA | |
| SCHEMBL424623 | 0.81 | ACP3 (0.50) | ACP3TSHRMEN1KMT2ALMNA | |
| SCHEMBL11606577 | 0.81 | ACP3 (0.50) | ACP3TSHRMEN1KMT2ALMNA | |
| SCHEMBL29403128 | 0.81 | ACP3 (0.50) | ACP3TSHRMEN1KMT2ALMNA | |
| SCHEMBL4375119 | 0.81 | ACP3 (0.50) | ACP3TSHRMEN1KMT2ALMNA | |
| SCHEMBL6225449 | 0.81 | ACP3 (0.50) | ACP3TSHRMEN1KMT2ALMNA | |
| SCHEMBL16950869 | 0.81 | ACP3 (0.43) | ACP3TSHRMEN1KMT2AADRB2 | |
| SCHEMBL16951935 | 0.80 | ACP3 (0.46) | ACP3TSHRMEN1KMT2ALMNA | |
| SCHEMBL19390817 | 0.79 | ACP3 (0.48) | ACP3TSHRMEN1KMT2ALMNA | |
| SCHEMBL25310844 | 0.77 | ALDH1A1 (0.44) | ACP3TSHRALDH1A1AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105143207-A | Substituted pyridine and substituted pyrazine compounds as PDE4 inhibitors | DART NEUROSCIENCE LLC | 2015-12-09 | — | — | CN | claimed |
| CN-101155781-B | Pyridine-3-carboxamide derivatives as cb1 inverse agonists | HOFFMANN LA ROCHE | 2012-11-07 | — | — | CN | claimed |
| CN-101155781-A | Pyridine-3-carboxamide derivatives as cb1 inverse agonists | HOFFMANN LA ROCHE (CH) | 2008-04-02 | — | — | CN | claimed |
| US-20240199612-A1 | IMIDAZOPYRIDINYL INHIBITORS OF PLASMA KALLIKREIN | SHIRE HUMAN GENETIC THERAPIES (US) | 2024-06-20 | — | — | US | disclosed |
| EP-4308227-A1 | IMIDAZOPYRIDINYL INHIBITORS OF PLASMA KALLIKREIN | Takeda Pharmaceutical Company Limited (JP) | 2024-01-24 | — | — | EP | disclosed |
| CN-117396473-A | Imidazopyridinyl inhibitors of plasma kallikrein | 武田药品工业株式会社 | 2024-01-12 | — | — | CN | disclosed |
| WO-2022197755-A1 | IMIDAZOPYRIDINYL INHIBITORS OF PLASMA KALLIKREIN | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| CN-105492432-A | Tetrazolinone compound and use thereof | SUMITOMO CHEMICAL CO | 2016-04-13 | — | — | CN | disclosed |
| CN-105143207-A | Substituted pyridine and substituted pyrazine compounds as PDE4 inhibitors | DART NEUROSCIENCE LLC | 2015-12-09 | — | — | CN | disclosed |
| CN-102532162-B | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMA CO LTD | 2015-05-27 | — | — | CN | disclosed |
| CN-104271571-A | Tetrazolinone compound and use thereof | SUMITOMO CHEMICAL CO | 2015-01-07 | — | — | CN | disclosed |
| CN-1067053-A | Pyrazines derivatives and preparation method thereof | OTSUKA PHARMA CO LTD (JP) | 1992-12-16 | — | — | CN | disclosed |
| US-5071856-A | CARBOSTYRIL DERIVATIVES AND SALTS THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-12-10 | — | — | US | disclosed |
| CN-1049155-A | INDOLE DERIVATIVES | OTSUKA CHEMICAL CO LTD (JP) | 1991-02-13 | — | — | CN | disclosed |
| EP-0400011-A1 | NEW PHENYLETHANOLAMINES. | BOEHRINGER INGELHEIM VETMED (DE) | 1990-12-05 | — | — | EP | disclosed |
| EP-0375791-A1 | Phenyl ethanol amines, their use as pharmaceutical compounds and as performance stimulants in animals, as well as processes for their preparation | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 1990-07-04 | — | — | EP | disclosed |
| WO-1990006299-A1 | NEW PHENYLETHANOLAMINES | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 1990-06-14 | — | — | WO | disclosed |
| US-4886809-A | CARDIOTONIC AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1989-12-12 | — | — | US | disclosed |
| EP-0255134-A2 | Carbostyril derivatives and salts thereof, process for preparing them, and cardiotonic composition containing same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1988-02-03 | — | — | EP | disclosed |
| EP-0171702-A1 | Benzoxazinone derivatives, preparation and use | BEECHAM GROUP PLC (GB) | 1986-02-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199612-A1 | IMIDAZOPYRIDINYL INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK1, KLK4 | ACP3 723/4885TSHR 3255/4885MEN1 1066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.